Combination, Prevention, and New Biology in Neurodegenerative Drug Development

Session details:

Neurodegenerative drug development is evolving beyond single-pathway and anti-amyloid–centric approaches toward combination strategies, earlier intervention, and expanded biological targets. Advances in biomarkers, genetics, and imaging are enabling more precise patient selection and earlier trials, while recent approvals are reshaping regulatory and development expectations. 
 
Key discussion points: 
•  Combination strategies: Designing and sequencing multi-mechanism approaches beyond monotherapy while managing safety, endpoints, and regulatory risk. 
•  Prevention and early intervention: Trial design, biomarkers, and evidence models for pre-symptomatic and early-stage populations. 
• New biology to execution: Incorporating neuroinflammation, synaptic dysfunction, and metabolic drivers into scalable development strategies.